All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Featured
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, How do response rates observed in clinical trials translate into real-world outcomes in multiple myeloma?
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Kumar discusses the characteristics of patients in clinical trials versus those treated in the real-world setting, highlighting the stringent inclusion/exclusion criteria and their impact on the generalizability of clinical trial results. He then explores how risk status, drug toxicity, and tolerability impact the real-world effectiveness of treatment. Kumar concludes by highlighting the differences between initial response rates seen in clinical trials and how this translates into longer-term outcomes, such as durability of response and progression-free survival.
Your opinion matters
28 votes - 4 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox